101. Induced pluripotent stem cell line from an atopic dermatitis patient heterozygous for c.2282del4 mutation in filaggrin: KCLi001-A
- Author
-
Devito, Liani, Donne, Matthew, Kolundzic, Nikola, Khurana, Preeti, Hobbs, Carl, Kaddour, Gabriel, Dubrac, Sandrine, Gruber, Robert, Schmuth, Matthias, Mauro, Thea, and Ilic, Dusko
- Subjects
Medical Biotechnology ,Biomedical and Clinical Sciences ,Stem Cell Research - Induced Pluripotent Stem Cell - Human ,Genetics ,Regenerative Medicine ,Stem Cell Research - Induced Pluripotent Stem Cell ,Stem Cell Research ,Dermatitis ,Atopic ,Female ,Filaggrin Proteins ,Heterozygote ,Humans ,Induced Pluripotent Stem Cells ,Intermediate Filament Proteins ,Mutation ,Biological Sciences ,Medical and Health Sciences ,Developmental Biology ,Medical biotechnology ,Oncology and carcinogenesis - Abstract
We have generated an induced pluripotent stem cell (iPSC) line KCLi001-A (iOP118) from a female atopic dermatitis (AD) patient, heterozygous for the loss-of-function mutation c.2282del4 in the filaggrin gene (FLG). Epidermal keratinocytes were reprogrammed using non-integrating Sendai virus vectors. The entire process of derivation and expansion of AD-iPSCs were performed under xeno-free culture conditions. Characterization of KCLi001-A line included molecular karyotyping, mutation screening using restriction enzyme digestion and Sanger sequencing, while pluripotency and differentiation potential were confirmed by expression of associated markers in vitro and by in vivo teratoma assay.
- Published
- 2018